Search results for " chemiotherapy"

showing 2 items of 2 documents

Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4

2008

We investigated the mechanisms involved in the resistance to cell death observed in epithelial cancers. Here, we identify that primary epithelial cancer cells from colon, breast and lung carcinomas express high levels of the antiapoptotic proteins PED, cFLIP, Bcl-xL and Bcl-2. These cancer cells produced interleukin-4 (IL-4), which amplified the expression levels of these antiapoptotic proteins and prevented cell death induced upon exposure to TRAIL or other drug agents. IL-4 blockade resulted in a significant decrease in the growth rate of epithelial cancer cells and sensitized them, both in vitro and in vivo, to apoptosis induction by TRAIL and chemotherapy via downregulation of the antia…

AdultMaleProgrammed cell deathLung NeoplasmsTime Factorsapoptosis interleukin-4 cancer stem cells cancer chemiotherapy cytokinesCASP8 and FADD-Like Apoptosis Regulating Proteinbcl-X ProteinAntineoplastic AgentsApoptosisBreast NeoplasmsBiologyTNF-Related Apoptosis-Inducing LigandTumor Cells CulturedmedicineHumansAutocrine signallingMolecular BiologyInterleukin 4AgedCell ProliferationSettore MED/04 - Patologia GeneraleCell DeathDose-Response Relationship DrugCell growthCarcinomaIntracellular Signaling Peptides and ProteinsAntibodies MonoclonalInterleukin-4 Receptor alpha SubunitCorrectionCancerCell BiologyMiddle AgedPhosphoproteinsmedicine.diseaseUp-RegulationCell biologyAutocrine CommunicationProto-Oncogene Proteins c-bcl-2Drug Resistance NeoplasmApoptosisColonic NeoplasmsCancer cellFemaleInterleukin-4Interleukin-4 Cancer stem cellsSignal transductionApoptosis Regulatory ProteinsSignal Transduction
researchProduct

Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: An Italian clinical experience

2011

Aims and Background: We investigated the efficacy of docetaxel plus prednisone in Italian patients with metastatic hormone- refractory prostate cancer (mHRPC). Methods: Twenty four patients with mHRPC received docetaxel 75 mg/m2 every 3 weeks plus prednisone 5 mg twice daily for up to six cycles. The primary endpoint was efficacy measured by a reduction in serum prostate specific antigen (PSA) levels and measurable disease. Evaluation of toxicity, quality of life and reduction of pain were secondary endpoints. Results: PSA response was seen in 18 patients (75%). We observed a partial response in 2 patients (8.3%), stable disease in 10 patients (41.7%), and disease progression in 12 patients…

Aged 80 and overMaleTime FactorsAntineoplastic Agents HormonalSettore MED/06 - Oncologia MedicaProstatic NeoplasmsDocetaxelAdenocarcinomaMiddle AgedProstate-Specific AntigenTreatment OutcomeItalyDrug Resistance NeoplasmAntineoplastic Combined Chemotherapy ProtocolsDisease ProgressionHumansPrednisoneTaxoidsAdenocarcinoma Antineoplastic combined chemiotherapy protocols Docetaxel Drug-resistace Neoplasm Prednisone Prostatic neoplasm TaxoidsAgedNeoplasm Staging
researchProduct